Printer Friendly

ALKERMES OVER-ALLOTMENT FULLY EXERCISED

 ALKERMES OVER-ALLOTMENT FULLY EXERCISED
 CAMBRIDGE, Mass., Nov. 20 /PRNewswire/ -- Alkermes, Inc.


(NASDAQ: ALKS) today announced that the underwriters of the company's recently completed public offering have fully exercised their option to purchase 300,000 additional shares of common stock to cover over-allotments from the offering.
 As a result of the purchase of the shares by the underwriters, managed by Robertson, Stephens & Company (San Francisco) and J.P. Morgan Securities Inc. (New York), a total of 2.3 million shares, including the over-allotment, were sold through the offering at a price to the public of $17.50 per share.
 Alkermes, Inc. is a neuropharmaceutical company founded in 1987 that is focused on the development and commercialization of therapeutic and diagnostic products for the treatment of disorders of the central nervous system.
 Copies of the prospectus relating to the offering may be obtained from Robertson, Stephens & Company, One Embarcadero Center, 31st Floor, San Francisco, CA 94111, or J.P. Morgan Securities Inc., 60 Wall St., New York, N.Y. 10260.
 -0- 11/20/91
 /CONTACT: Michael J. Landine, chief financial officer of Alkermes, 617-494-0171, or Thomas A. Pearson of Pearson Communications, 215-648-3975, for Alkermes/
 (ALKS) CO: Alkermes, Inc. ST: Massachusetts IN: MTC SU:


SH -- NE009 -- 5408 11/20/91 12:13 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 20, 1991
Words:210
Previous Article:AMERICAN HOME PRODUCTS AND ALZA ENTER JOINT RESEARCH, DEVELOPMENT AND MARKETING AGREEMENT
Next Article:INTERMAGNETICS GENERAL AWARDED PROGRAM TO DESIGN MOTOR FOR MAGLEV VEHICLE
Topics:


Related Articles
UNDERWRITERS' OPTION EXERCISED IN ARAMED UNIT OFFERING AND GENSIA COMMON STOCK OFFERING
ALKERMES RECEIVES PATENT ON RMP TECHNOLOGY
MedImmune and Alkermes Sign Agreement to Develop Pulmonary Delivery System For Monoclonal Antibody Against Respiratory Syncytial Virus.
Amylin Pharmaceuticals Announces Successful Completion of AC2993 LAR Feasibility Work with Alkermes and Plans for Human Studies in 2001.
Exenatide LAR Data Support Initiation of Phase 2 Multi-Dose Study in 2005.
Lilly and Alkermes Complete Patient Enrollment for Phase 3 Safety Study for Inhaled Insulin for the Treatment of Diabetes.
Investigational Once-Weekly Exenatide Demonstrated Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters